The COSMAM TRIAL a prospective cohort study of quality of life and cosmetic outcome in patients undergoing breast conserving surgery

Background Cosmetic result in breast cancer surgery is gaining increased interest. Currently, some 30–40% of the patients treated with breast conserving surgery (BCS) are dissatisfied with their final cosmetic result. In order to prevent disturbing breast deformity oncoplastic surgical techniques have been introduced. The extent of different levels of oncoplastic surgery incorporated in breast conserving surgery and its value with regard to cosmetic outcome, patient satisfaction and quality of life remains to be defined. The aim of this prospective cohort study is to investigate quality of life and satisfaction with cosmetic result in patients with breast cancer, undergoing standard lumpectomy versus level I or II oncoplastic breast conserving surgery. Methods Female breast cancer patients scheduled for BCS, from 18 years of age, referred to our outpatient clinic from July 2015 are asked to participate in this study. General, oncologic and treatment information will be collected. Patient satisfaction will be scored preceding surgery, and at 1 month and 1 year follow up. Photographs of the breast will be used to score cosmetic result both by the patient, an independent expert panel and BCCT.Core software. Quality of life will be measured by using the BREAST-Q BCT, EORTC-QLQ and EQ-5D-5 L questionnaires. Discussion The purpose of this prospective study is to determine the clinical value of different levels of oncoplastic techniques in breast conserving surgery, with regard to quality of life and cosmetic result. Analysis will be carried out by objective measurements of the final cosmetic result in comparison with standard breast conserving surgery. The results of this study will be used to development of a clinical decision model to guide the use oncoplastic surgery in future BCS. Trial registration Central Commission of Human Research (CCMO), The Netherlands: NL54888.015.15. Medical Ethical Commission (METC), Maxima Medical Centre, Veldhoven, The Netherlands: 15.107. Dutch Trial Register: NTR5665, retrospectively registered, 02-25-2016. Electronic supplementary material The online version of this article (10.1186/s12885-018-4368-8) contains supplementary material, which is available to authorized users.

Tags
Data and Resources
To access the resources you must log in

This item has no data

Identity

Description: The Identity category includes attributes that support the identification of the resource.

Field Value
PID https://www.doi.org/10.1186/s12885-018-4368-8
PID pmc:PMC5914027
PID pmid:29688847
PID urn:urn:nbn:nl:ui:27-eb49999d-1519-408d-b58b-f6894144e9e1
URL http://link.springer.com/article/10.1186/s12885-018-4368-8/fulltext.html
URL http://dx.doi.org/10.1186/s12885-018-4368-8
URL https://dx.doi.org/10.1186/s12885-018-4368-8
URL https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4368-8
URL http://europepmc.org/articles/PMC5914027
URL https://www.narcis.nl/publication/RecordID/oai%3Acris.maastrichtuniversity.nl%3Apublications%2Feb49999d-1519-408d-b58b-f6894144e9e1
URL https://cris.maastrichtuniversity.nl/en/publications/eb49999d-1519-408d-b58b-f6894144e9e1
URL https://doi.org/10.1186/s12885-018-4368-8
URL https://www.ncbi.nlm.nih.gov/pubmed/29688847
URL http://link.springer.com/article/10.1186/s12885-018-4368-8
URL https://link.springer.com/article/10.1186/s12885-018-4368-8
URL https://doaj.org/toc/1471-2407
URL http://link.springer.com/content/pdf/10.1186/s12885-018-4368-8.pdf
URL https://academic.microsoft.com/#/detail/2805817729
URL https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-018-4368-8
Access Modality

Description: The Access Modality category includes attributes that report the modality of exploitation of the resource.

Field Value
Access Right Open Access
Attribution

Description: Authorships and contributors

Field Value
Author Adri Voogd, 0000-0002-8041-2720
Contributor RS: GROW - R2 - Innovative Cancer Diagnostics & Therapy
Contributor RS: CAPHRI - R5 - Optimising Patient Care
Contributor Epidemiologie
Contributor MUMC+: BC - Medische Oncologie
Publishing

Description: Attributes about the publishing venue (e.g. journal) and deposit location (e.g. repository)

Field Value
Collected From Europe PubMed Central; PubMed Central; ORCID; Datacite; UnpayWall; DOAJ-Articles; NARCIS; Crossref; Microsoft Academic Graph
Hosted By Europe PubMed Central; BMC Cancer; NARCIS; UM Publications
Journal BMC Cancer, ,
Publication Date 2018-04-23
Publisher BMC
Additional Info
Field Value
Country Netherlands
Language English
Resource Type Other literature type; Article; UNKNOWN
system:type publication
Management Info
Field Value
Source https://science-innovation-policy.openaire.eu/search/publication?articleId=dedup_wf_001::76c013ab454ec59e3dd0670f3a28180a
Author jsonws_user
Last Updated 21 December 2020, 14:49 (CET)
Created 21 December 2020, 14:49 (CET)